[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-gastroenteropancreatic-neuroendocrine-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-gastroenteropancreatic-neuroendocrine-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100507197","phase-3-an-open-label-phase-3-study-of-lutetium-177lu-oxodotreotide-injection-in-subjects-with-advanced-gastrointestinal-pancreatic-neuroendocrine-tumors-100507197",false,"NCT05884255","An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent;\n2. 18\\~75 years old,male or female;\n3. ECOG performance status 0 or 1;\n4. Unresectable locally advanced or metastatic gastrointestinal neuroendocrine tumors (GEP-NETs) of low and medium grade (G1 or G2) confirmed by histopathology.\n\nExclusion Criteria:\n\n1. Central nervous system metastasis is known. Patients who have previously received treatment ( radiotherapy or surgery ) for brain metastases and have no clinical symptoms can be enrolled if the pre-randomized pre-imaging is confirmed to be stable for at least 24 weeks;\n2. There are clinical symptoms or diseases of the heart that are not well controlled;\n3. Diabetes (fasting blood glucose \\> 2 × ULN) that cannot be well controlled after optimal medical support treatment;\n4. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction or indwelling catheter for any reason.","ALL","18 Years","75 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.",[27],"Advanced Gastroenteropancreatic Neuroendocrine Tumor","RECRUITING","2026-05-15",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":32},"2023-07-06",{"date":36,"type":21},"2030-10",{"name":38,"class":39},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",2]